Literature DB >> 27488350

Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression.

Ludovic Belle1, Kimberle Agle1, Vivian Zhou1, Cheng Yin-Yuan1, Richard Komorowski2, Daniel Eastwood3, Brent Logan3, Jie Sun4, Nico Ghilardi5, Daniel Cua6, Calvin B Williams7, Melanie Gaignage8, Reece Marillier9, Jacques van Snick9, William R Drobyski1.   

Abstract

Reestablishment of competent regulatory pathways has emerged as a strategy to reduce the severity of graft-versus-host disease (GVHD), and recalibrate the effector and regulatory arms of the immune system. However, clinically feasible, cost-effective strategies that do not require extensive ex vivo cellular manipulation have remained elusive. In the current study, we demonstrate that inhibition of the interleukin-27p28 (IL-27p28) signaling pathway through antibody blockade or genetic ablation prevented lethal GVHD in multiple murine transplant models. Moreover, protection from GVHD was attributable to augmented global reconstitution of CD4+ natural regulatory T cells (nTregs), CD4+ induced Tregs (iTregs), and CD8+ iTregs, and was more potent than temporally concordant blockade of IL-6 signaling. Inhibition of IL-27p28 also enhanced the suppressive capacity of adoptively transferred CD4+ nTregs by increasing the stability of Foxp3 expression. Notably, blockade of IL-27p28 signaling reduced T-cell-derived-IL-10 production in conventional T cells; however, there was no corresponding effect in CD4+ or CD8+ Tregs, indicating that IL-27 inhibition had differential effects on IL-10 production and preserved a mechanistic pathway by which Tregs are known to suppress GVHD. Targeting of IL-27 therefore represents a novel strategy for the in vivo expansion of Tregs and subsequent prevention of GVHD without the requirement for ex vivo cellular manipulation, and provides additional support for the critical proinflammatory role that members of the IL-6 and IL-12 cytokine families play in GVHD biology.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27488350      PMCID: PMC5073185          DOI: 10.1182/blood-2016-02-698241

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

1.  Regulatory T cell development in the absence of functional Foxp3.

Authors:  Wen Lin; Dipica Haribhai; Lance M Relland; Nga Truong; Marc R Carlson; Calvin B Williams; Talal A Chatila
Journal:  Nat Immunol       Date:  2007-02-02       Impact factor: 25.606

2.  Tocilizumab for the treatment of steroid refractory graft-versus-host disease.

Authors:  William R Drobyski; Marcelo Pasquini; Kathy Kovatovic; Jeanne Palmer; J Douglas Rizzo; Ayman Saad; Wael Saber; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-13       Impact factor: 5.742

3.  Development of Th1-type immune responses requires the type I cytokine receptor TCCR.

Authors:  Q Chen; N Ghilardi; H Wang; T Baker; M H Xie; A Gurney; I S Grewal; F J de Sauvage
Journal:  Nature       Date:  2000-10-19       Impact factor: 49.962

4.  A role for IL-27 in limiting T regulatory cell populations.

Authors:  Elia D Tait Wojno; Nancy Hosken; Jason S Stumhofer; Aisling C O'Hara; Elizabeth Mauldin; Qun Fang; Laurence A Turka; Steven D Levin; Christopher A Hunter
Journal:  J Immunol       Date:  2011-05-27       Impact factor: 5.422

Review 5.  Graft-versus-host disease.

Authors:  Warren D Shlomchik
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

6.  IL-12 is a central mediator of acute graft-versus-host disease in mice.

Authors:  E Williamson; P Garside; J A Bradley; A M Mowat
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

7.  Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.

Authors:  Keli L Hippen; Sarah C Merkel; Dawn K Schirm; Christine M Sieben; Darin Sumstad; Diane M Kadidlo; David H McKenna; Jonathan S Bromberg; Bruce L Levine; James L Riley; Carl H June; Phillip Scheinberg; Daniel C Douek; Jeffrey S Miller; John E Wagner; Bruce R Blazar
Journal:  Sci Transl Med       Date:  2011-05-18       Impact factor: 17.956

8.  A novel role for IL-27 in mediating the survival of activated mouse CD4 T lymphocytes.

Authors:  Gisen Kim; Ryo Shinnakasu; Christiaan J M Saris; Hilde Cheroutre; Mitchell Kronenberg
Journal:  J Immunol       Date:  2013-01-18       Impact factor: 5.422

9.  Association of Foxp3 regulatory gene expression with graft-versus-host disease.

Authors:  Yuji Miura; Christopher J Thoburn; Emilie C Bright; Michele L Phelps; Tahiro Shin; Elizabeth C Matsui; William H Matsui; Sally Arai; Ephraim J Fuchs; Georgia B Vogelsang; Richard J Jones; Allan D Hess
Journal:  Blood       Date:  2004-06-01       Impact factor: 22.113

Review 10.  Biology of recently discovered cytokines: discerning the pro- and anti-inflammatory properties of interleukin-27.

Authors:  Alejandro V Villarino; Christopher A Hunter
Journal:  Arthritis Res Ther       Date:  2004-08-16       Impact factor: 5.156

View more
  23 in total

Review 1.  Cytokines and costimulation in acute graft-versus-host disease.

Authors:  Geoffrey R Hill; Motoko Koyama
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

2.  Eomesodermin promotes the development of type 1 regulatory T (TR1) cells.

Authors:  Ping Zhang; Jason S Lee; Kate H Gartlan; Iona S Schuster; Iain Comerford; Antiopi Varelias; Md Ashik Ullah; Slavica Vuckovic; Motoko Koyama; Rachel D Kuns; Kelly R Locke; Kirrilee J Beckett; Stuart D Olver; Luke D Samson; Marcela Montes de Oca; Fabian de Labastida Rivera; Andrew D Clouston; Gabrielle T Belz; Bruce R Blazar; Kelli P MacDonald; Shaun R McColl; Ranjeny Thomas; Christian R Engwerda; Mariapia A Degli-Esposti; Axel Kallies; Siok-Keen Tey; Geoffrey R Hill
Journal:  Sci Immunol       Date:  2017-04-07

3.  IL-27: a new target for GVHD prevention.

Authors:  Daniel H Fowler; Shoba Amarnath
Journal:  Blood       Date:  2016-10-20       Impact factor: 22.113

Review 4.  Regulatory T Cell Plasticity and Stability and Autoimmune Diseases.

Authors:  Runze Qiu; Liyu Zhou; Yuanjing Ma; Lingling Zhou; Tao Liang; Le Shi; Jun Long; Dongping Yuan
Journal:  Clin Rev Allergy Immunol       Date:  2020-02       Impact factor: 8.667

5.  IL-27 Promotes Human Placenta-Derived Mesenchymal Stromal Cell Ability To Induce the Generation of CD4+IL-10+IFN-γ+ T Cells via the JAK/STAT Pathway in the Treatment of Experimental Graft-versus-Host Disease.

Authors:  Junzhu Yi; Zhenghua Chen; Fenghuang Xu; ZhuoYa Wang; Aiping Zhang; Tongshen Liu; Nannan Zhao; Yanlian Xiong; Guosheng Jiang; Junjie Ma; Xiying Luan
Journal:  J Immunol       Date:  2019-01-16       Impact factor: 5.422

6.  A folding switch regulates interleukin 27 biogenesis and secretion of its α-subunit as a cytokine.

Authors:  Stephanie I Müller; Antonie Friedl; Isabel Aschenbrenner; Julia Esser-von Bieren; Martin Zacharias; Odile Devergne; Matthias J Feige
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-16       Impact factor: 11.205

Review 7.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.

Authors:  Bruce R Blazar; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

8.  IL-27 regulates the adherence, proliferation, and migration of MSCs and enhances their regulatory effects on Th1 and Th2 subset generations.

Authors:  Fenghuang Xu; Junzhu Yi; Zhuoya Wang; Yejia Hu; Chunlei Han; Qun Xue; Xueguang Zhang; Xiying Luan
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

9.  β2-Adrenergic receptor activation on donor cells ameliorates acute GvHD.

Authors:  Hemn Mohammadpour; Joseph L Sarow; Cameron R MacDonald; George L Chen; Jingxin Qiu; Umesh C Sharma; Xuefang Cao; Megan M Herr; Theresa E Hahn; Bruce R Blazar; Elizabeth A Repasky; Philip L McCarthy
Journal:  JCI Insight       Date:  2020-06-18

10.  A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.

Authors:  Sendhilnathan Ramalingam; Sharareh Siamakpour-Reihani; Lauren Bohannan; Yi Ren; Alexander Sibley; Jeff Sheng; Li Ma; Andrew B Nixon; Jing Lyu; Daniel C Parker; James Bain; Michael Muehlbauer; Olga Ilkayeva; Virginia Byers Kraus; Janet L Huebner; Thomas Spitzer; Jami Brown; Jonathan U Peled; Marcel van den Brink; Antonio Gomes; Taewoong Choi; Cristina Gasparetto; Mitchell Horwitz; Gwynn Long; Richard Lopez; David Rizzieri; Stefanie Sarantopoulos; Nelson Chao; Anthony D Sung
Journal:  PLoS One       Date:  2021-06-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.